Should I Buy CMMB? CMMB 2026 Analysis

Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.530

1 Day change

5.52%

52 Week Range

8.610

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no proprietary buy signals.
Short-term edge looks weak: pattern-based stats point to slightly negative drift over the next day/week/month.
Best read is “wait/avoid entry” unless price reclaims key levels (pivot ~1.68 and then 1.80+) with improving momentum and volume.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Price/levels: trading below pivot (~1.68); immediate support S1 ~1.556 (then S2 ~1.479). Resistance at R1 ~1.804 then R2 ~1.881.
Trend: bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) indicates the bigger trend is still down.
Momentum: MACD histogram is positive and expanding (0.0139), suggesting a developing rebound, but it hasn’t flipped the broader trend.
RSI (6): 43.78 (neutral-to-soft), not showing strong buying pressure.
Quant/pattern outlook provided: ~60% chance of modest downside (-0.25% next day, -0.57% next week, -0.68% next month), aligning with “no rush to buy.”

Positive Catalysts

and holds.

Neutral/Negative Catalysts

- No news in the past week: no clear event-driven catalyst to force a re-rating upward.
- Bearish moving-average structure signals rallies may fail until trend improves.
- Statistical/pattern-based expectation provided is mildly negative across near-term horizons.
- Congress trading: No recent congress trading data available (no supportive signal from that channel).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) — effectively no operating revenue contribution.
Net income: -1,742,000 (down -49.99% YoY) — losses widened significantly.
EPS: 0 (down -100.00% YoY as provided) — profitability trend not improving in the snapshot.
Overall: growth/profitability picture in the latest quarter snapshot is weak, which reduces fundamental support for an impatient “buy now” entry.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so a Wall Street pros/cons read can’t be confirmed from the dataset.
Practical implication: without fresh upgrades/targets as a catalyst, the setup relies mainly on technicals—which are currently mixed-to-bearish.

2 Analyst Rating

Wall Street analysts forecast CMMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMMB is 17.5 USD with a low forecast of 10 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.450

Low

Averages

17.5

High

Current: 1.450

Low

Averages

17.5

High

Oppenheimer

Outperform

maintain

$10 -> $25

AI Analysis

2025-08-27

Reason

Oppenheimer

Price Target

$10 -> $25

AI Analysis

2025-08-27

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Chemomab Therapeutics to $25 from $10 and keeps an Outperform rating on the shares to reflect Q2 results and management's intent to advance nebokitug in primary sclerosing cholangitis solely based on a third-party partnership, licensing or other similar transaction. The firm, which notes that its raised target reflects the potential value it sees to shareholders under an M&A or licensing scenario, points out that it also accounts for the company's 4-to-1 reverse share split.

Oppenheimer

Jeff Jones

Outperform

downgrade

$11 -> $10

2025-05-16

Reason

Oppenheimer

Jeff Jones

Price Target

$11 -> $10

2025-05-16

downgrade

Outperform

Reason

Oppenheimer analyst Jeff Jones lowered the firm's price target on Chemomab Therapeutics to $10 from $11 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 financial results, highlighting recent updates, including regulatory feedback providing clear guidance on approvable endpoints for nebokitug in PSC, and recent positive 48 weeks SPRING OLE results.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMMB

Unlock Now

CMMB Should I Buy

CMMB Should I Buy

Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch